Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Net Income (2020 - 2025)

Historic Net Income for Barinthus Biotherapeutics (BRNS) over the last 6 years, with Q3 2025 value amounting to -$14.6 million.

  • Barinthus Biotherapeutics' Net Income fell 7924.71% to -$14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.9 million, marking a year-over-year decrease of 3120.83%. This contributed to the annual value of -$61.2 million for FY2024, which is 1669.78% up from last year.
  • Per Barinthus Biotherapeutics' latest filing, its Net Income stood at -$14.6 million for Q3 2025, which was down 7924.71% from -$21.1 million recorded in Q2 2025.
  • Over the past 5 years, Barinthus Biotherapeutics' Net Income peaked at $15.7 million during Q2 2022, and registered a low of -$23.8 million during Q2 2023.
  • In the last 5 years, Barinthus Biotherapeutics' Net Income had a median value of -$16.8 million in 2021 and averaged -$12.2 million.
  • As far as peak fluctuations go, Barinthus Biotherapeutics' Net Income soared by 24868.87% in 2022, and later crashed by 80796.43% in 2023.
  • Quarter analysis of 5 years shows Barinthus Biotherapeutics' Net Income stood at -$16.8 million in 2021, then decreased by 25.69% to -$21.2 million in 2022, then grew by 18.3% to -$17.3 million in 2023, then fell by 19.09% to -$20.6 million in 2024, then rose by 29.24% to -$14.6 million in 2025.
  • Its Net Income was -$14.6 million in Q3 2025, compared to -$21.1 million in Q2 2025 and -$19.7 million in Q1 2025.